摘要
背景:多形性成胶质细胞瘤(GBM)是在成年中最常见的脑瘤并且具有较低的存活率。肿瘤微环境的不一致性、耐药性、放射治疗以及它较强的侵略性都导致了不良后果。大量的与小神经胶质和巨噬细胞相关的成胶质瘤细胞(GAMs)能够在肿瘤发生的地方积累,这在预后中具有重要的作用。 方法:关于该主题现有文献使用PubMed数据库进行了广泛的修订,本文探索了小神经胶质和巨噬细胞相关的成胶质瘤细胞到多形性成胶质细胞瘤生物学的贡献以及有证据显示小神经胶质和巨噬细胞相关的成胶质细胞瘤可以被药物调控抑制肿瘤细胞的增长。 结果:小神经胶质和巨噬细胞相关的成胶质细胞瘤占据整个脑胶质瘤质量的30%,是最大的一个部分。与肿瘤细胞相互作用后,GAMs获得一个独特的激活表型,包括M1和M2特异性标记物。不同的激活类型通常共存于同一个以来GAM位置或者病理状态的肿瘤中。除了调控可能控制或者倾向于形成星形胶质细胞恶性转化的免疫应答外,GAMs直接参与细胞外基质降解,这是一种可以扩大肿瘤和实质侵犯的重要的机制。目前已经发展了几种药理学的方法,包括干扰GAM在肿瘤部位、细胞分化和免疫功能方面的聚集,并通过GAM重塑ECM分泌因子。最有前途的治疗方法似乎是以GBM和GAM生物学特征为研究目标。 结论:GAMs明显有助于GAM生物学研究(倾向于肿瘤的生长和侵略)。本文所综述的数据表明这些细胞代表一个有价值的替代或者附加的靶点为GBM开发更多有效的治疗。
关键词: 成胶质细胞,小神经角质,巨噬细胞,M1,M2,NOS2,ARG-1,金属蛋白
图形摘要
Current Cancer Drug Targets
Title:Exploiting Microglial Functions for the Treatment of Glioblastoma
Volume: 17 Issue: 3
关键词: 成胶质细胞,小神经角质,巨噬细胞,M1,M2,NOS2,ARG-1,金属蛋白
摘要: Background: Glioblastoma multiforme (GBM) is the most common brain tumor in adults and is associated with a very low survival rate. The heterogeneity of the tumor microenvironment, its resistance to drug and radiation therapy, and its robust invasiveness all contribute to the poor outcome. Large numbers of glioma associated microglia and macrophages (GAMs) can accumulate within the tumor where they appear to have an important role in prognosis.
Methods: An extensive revision of current available literature on this topic has been carried out, using the PubMed database. Articles exploring the contribution of GAMs to GBM biology as well as evidence that GAMs can be pharmacologically modulated to inhibit tumor growth are critically discussed in this review article. Results: GAMs constitute the largest portion of tumor infiltrating cells contributing up to 30% of the entire glioma mass. Upon interaction with neoplastic cells, GAMs acquire a unique phenotype of activation including both M1 and M2 specific markers. Different profiles of activation usually co-exist in the same tumor that is dependent upon GAM location or stage of disease. In addition to regulating immune responses which may control or favor astrocyte malignant transformation, GAMs are directly involved in the degradation of the extracellular matrix (ECM), a crucial mechanism that allows the expansion of tumors and parenchyma invasion. Several pharmacological strategies have been developed which interfere with GAM recruitment at the tumor site, cell polarization and immune function, and ECM remodeling by GAM-secreted factors. The most promising therapeutic approaches appear to target both GBM cells and GAM biological properties. Conclusion: GAMs significantly contribute to GBM biology (favoring tumor growth and invasiveness). Data reviewed in the present article suggest that these cells represent a valuable alternative/ additional target for the development of more effective treatments for GBM.Export Options
About this article
Cite this article as:
Exploiting Microglial Functions for the Treatment of Glioblastoma, Current Cancer Drug Targets 2017; 17 (3) . https://dx.doi.org/10.2174/1568009616666160813191240
DOI https://dx.doi.org/10.2174/1568009616666160813191240 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) Electrohydrodynamic Preparation of Nanomedicines
Current Topics in Medicinal Chemistry Uridine Function in the Central Nervous System
Current Topics in Medicinal Chemistry Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry The Metabolism of Anthocyanins
Current Drug Metabolism Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry microRNAs: Innovative Targets for Cerebral Ischemia and Stroke
Current Drug Targets Influence of Trishomocubanes on Sigma Receptor Binding of N-(1-Benzylpiperidin- 4-yl)-4-[123I]iodobenzamide In Vivo in the Rat Brain
Medicinal Chemistry Combined Treatment with JFKD and Gefitinib Overcomes Drug Resistance in Non-Small Cell Lung Cancer
Current Pharmaceutical Biotechnology MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Technologies for Translational Imaging Using Generators in Oncology
Recent Patents on Anti-Cancer Drug Discovery New Prospects for Nelfinavir in Non-HIV-Related Diseases
Current Molecular Pharmacology Ferroptosis: A Novel Mechanism of Artemisinin and its Derivatives in Cancer Therapy
Current Medicinal Chemistry Meet Our Editorial Board Member
Letters in Drug Design & Discovery Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology Chitosan Derivatives with Antimicrobial, Antitumour and Antioxidant Activities - a Review
Current Pharmaceutical Design Arachidonic Acid Induces the Migration of MDA-MB-231 Cells by Activating Raft-associated Leukotriene B4 Receptors
Clinical Cancer Drugs Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine